BA
GALT icon

BlackRock Advisors’s Galectin Therapeutics GALT Stock Holding History

BlackRock Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-9,174
Closed -$31K – 3720
2015
Q1 		$31K Buy
9,174
+1,631
+22% +$5.83K ﹤0.01% 3352
2014
Q4 		$26K Hold
7,543
– – ﹤0.01% 3436
2014
Q3 		$38K Hold
7,543
– – ﹤0.01% 3337
2014
Q2 		$104K Buy
+7,543
New +$93.9K ﹤0.01% 3029

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Advisors's GALT Position: Q2 2015 in Review

BlackRock Advisors sold out of Galectin Therapeutics (GALT) in Q2 2015, closing a stake of 9,174 shares — an estimated $31K sold.

BlackRock Advisors first reported a position in GALT in Q2 2014 and held it in 4 quarters. The position peaked at $104K in Q2 2014. 58 funds tracked by Wall St. Rank hold GALT as of Q2 2015.

  • BlackRock Advisors reported no remaining Galectin Therapeutics position as of Q2 2015 after selling out during the quarter.
  • BlackRock Advisors sold 9,174 Galectin Therapeutics shares in Q2 2015, an estimated $31K.
  • BlackRock Advisors first reported a position in Galectin Therapeutics in Q2 2014 and held it in 4 quarters.
  • BlackRock Advisors's Galectin Therapeutics position peaked at $104K in Q2 2014.
  • 58 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2015.

Based on BlackRock Advisors's 13F filing for Q2 2015, filed 7 Aug 2015.